Mainz Biomed N.V. reported a significant decline in financial performance for the fiscal year ending December 31, 2025, with total revenue of $537,080, down 40% from $893,991 in 2024. The decrease in revenue was primarily attributed to the company's decision to wind down its direct-to-consumer business in August 2024, shifting focus to sales of its ColoAlert product to laboratory partners. The cost of sales also decreased by 54% to $147,288, resulting in a gross profit of $389,792, which improved the gross margin from 64% to 73%. However, the company recorded a net loss of $16.2 million, a 25% reduction from the previous year's loss of $21.6 million.
In terms of operational changes, Mainz Biomed underwent a strategic realignment in February 2026, deciding to cease the development of its ColoAlert and next-generation colorectal cancer screening products. This decision led to the termination of employees primarily involved in these projects and the sale of the intellectual property associated with ColoAlert. The company has since focused on developing a pancreatic cancer screening test, PancAlert, and has acquired a license for novel mRNA biomarkers and an AI algorithm for this purpose. The company also appointed David Lazar as co-CEO and Robert Liscouski as non-executive Chairman to guide this strategic shift.
The company’s workforce was significantly reduced, with a 65% decrease in personnel as part of its restructuring efforts. As of March 30, 2026, Mainz Biomed had approximately 10 full-time and 3 part-time employees. The company also reported an impairment loss of $2.64 million on its intangible assets, primarily due to the closure of its colorectal cancer product line. The total operating expenses for 2025 were $16.5 million, down 15% from $19.3 million in 2024, reflecting cost-cutting measures implemented during the restructuring.
Looking ahead, Mainz Biomed's outlook remains cautious. The company has indicated that it may require additional funding to support its operations and development efforts, particularly for the pancreatic cancer screening product. As of December 31, 2025, the company had cash and cash equivalents of $889,091 and a working capital deficit of $1.9 million. The company is exploring various financing options, including public or private offerings, to address its liquidity needs. Additionally, Mainz Biomed has received a notification from Nasdaq regarding a deficiency in meeting the minimum bid price requirement, which could impact its listing status if not resolved by September 2026.
Overall, Mainz Biomed is navigating a challenging financial landscape while attempting to pivot its business strategy towards promising new diagnostic technologies. The company's ability to secure funding and successfully develop its pancreatic cancer screening test will be critical to its future viability.
About MAINZ BIOMED N.V.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.